Ayşe Çiğdem Sivrice
Research Subjects
Ayşe Çiğdem Sivrice has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Nur Akınel2 shared publications
- Elif Güler
Division of Hematology and Oncology, Department of Pediatrics, Akdeniz University Hospital, 07070 Antalya, Turkey
2 shared publications - Funda Tayfun Küpesiz
Division of Pediatric Hematology and Oncology Akdeniz University Faculty of Medicine Antalya Türkiye
2 shared publications - Gülen Tüysüz
Akdeniz University Hospital, Department of Children's Health and Diseases, Antalya, Turkey
2 shared publications - Alphan Kupesiz
Division of Hematology, Department of Paediatrics, Faculty of Medicine, Akdeniz University, 07070 Antalya, Turkey
1 shared publication Alphan Küpesiz
1 shared publication
Latest Publications
- Open Access
- 1 July 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (4) , 419-421
Life-Threatening Recurrence of Paroxysmal Cold Hemoglobinuria in a Child During Influenza A Infection
Cite this article as: Maslak İC, Selver MB, Kaşkaya Ö, et al. Life-threatening recurrence of paroxysmal cold hemoglobinuria in a child during influenza A infection. Turk Arch Pediatr. 2024;59(4):419-421.
- 1 July 2024
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 59 (4) , 419-421
Open AccessLife-Threatening Recurrence of Paroxysmal Cold Hemoglobinuria in a Child During Influenza A Infection
Cite this article as: Maslak İC, Selver MB, Kaşkaya Ö, et al. Life-threatening recurrence of paroxysmal cold hemoglobinuria in a child during influenza A infection. Turk Arch Pediatr. 2024;59(4):419-421.
- Open Access
- 15 December 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (12) , 1069-1078
Multidisciplinary Management of Pediatric Hepatoblastoma: A 20-Year Single-Center Experience
Background: Hepatoblastoma is rare cancer that responds well to risk-based chemotherapy, and surgical treatment is needed to achieve complete remission and satisfactory survival rates in hepatoblastoma patients. In this study, we evaluated the clinical features and treatment outcomes of pediatric hepatoblastoma patients treated in our clinic. Methods: Eighteen patients with hepatoblastoma who were treated and followed up in our center between June 1999 and June 2020 were analyzed retrospectively. All patients were evaluated by a multidisciplinary team and managed using a risk-based protocol (SIOPEL-1 and SIOPEL-3). Results: The patients’ mean age at diagnosis was 38.33 ± 52.34 months. Sixteen patients (89%) received neoadjuvant chemotherapy, and 2 patients (11%) who underwent complete mass excision at diagnosis received adjuvant chemotherapy. After neoadjuvant therapy, the tumor was completely resected in 8 patients (45%), while liver transplantation was performed in 6 patients (34%) because complete resection of the tumor was not possible. Two patients died before surgical treatment. One patient relapsed with lung metastasis after salvage chemotherapy. She is alive without disease at 64 months. The mean follow-up time was 59.3 ± 49.8 months; 5-year overall and disease-free survival rates were 88.9% and 80.8%, respectively. The 5-year overall survival rate was 100% for both liver transplant and resected patients, whereas 5-year disease-free survival was lower in transplant patients (75% vs 100%, P < .001). Conclusion: Multidisciplinary follow-up is especially important for patients who may need liver transplantation. Some patients may benefit from new treatment options such as radiofrequency ablation and cyberknife treatment. Cite this article as: Tayfun Küpesiz F, Akınel AN, Akbaş H, et al. Multidisciplinary management of pediatric hepatoblastoma: A 20-year single-center experience. Turk J Gastroenterol. 2022;33(12):1069-1078.
- 15 December 2022
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 33 (12) , 1069-1078
Open AccessMultidisciplinary Management of Pediatric Hepatoblastoma: A 20-Year Single-Center Experience
Background: Hepatoblastoma is rare cancer that responds well to risk-based chemotherapy, and surgical treatment is needed to achieve complete remission and satisfactory survival rates in hepatoblastoma patients. In this study, we evaluated the clinical features and treatment outcomes of pediatric hepatoblastoma patients treated in our clinic. Methods: Eighteen patients with hepatoblastoma who were treated and followed up in our center between June 1999 and June 2020 were analyzed retrospectively. All patients were evaluated by a multidisciplinary team and managed using a risk-based protocol (SIOPEL-1 and SIOPEL-3). Results: The patients’ mean age at diagnosis was 38.33 ± 52.34 months. Sixteen patients (89%) received neoadjuvant chemotherapy, and 2 patients (11%) who underwent complete mass excision at diagnosis received adjuvant chemotherapy. After neoadjuvant therapy, the tumor was completely resected in 8 patients (45%), while liver transplantation was performed in 6 patients (34%) because complete resection of the tumor was not possible. Two patients died before surgical treatment. One patient relapsed with lung metastasis after salvage chemotherapy. She is alive without disease at 64 months. The mean follow-up time was 59.3 ± 49.8 months; 5-year overall and disease-free survival rates were 88.9% and 80.8%, respectively. The 5-year overall survival rate was 100% for both liver transplant and resected patients, whereas 5-year disease-free survival was lower in transplant patients (75% vs 100%, P < .001). Conclusion: Multidisciplinary follow-up is especially important for patients who may need liver transplantation. Some patients may benefit from new treatment options such as radiofrequency ablation and cyberknife treatment. Cite this article as: Tayfun Küpesiz F, Akınel AN, Akbaş H, et al. Multidisciplinary management of pediatric hepatoblastoma: A 20-year single-center experience. Turk J Gastroenterol. 2022;33(12):1069-1078.
- Open Access
- 25 August 2021
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 19 (2) , 176-184
Clinical Characteristics and Treatment Outcomes of Patients with Malignant Extracranial Germ Cell Tumors: A 20-Year Single-Center Experience
- 25 August 2021
- Published by Galenos Yayinevi in Güncel Pediatri
- Vol. 19 (2) , 176-184
Open AccessClinical Characteristics and Treatment Outcomes of Patients with Malignant Extracranial Germ Cell Tumors: A 20-Year Single-Center Experience